Anlotinib Recruiting Phase 2 Trials for Gastroenteropancreatic Neuroendocrine Tumor G3 Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03457844A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3